Epidermolysis bullosa aquisita (EBA) is a heavy autoantibody-mediated bullous dermatosis. The antibodys bind at the antigen Collagen Typ 7 (Col 7). This leads to the activation oft he complementsystem in skin and muccosa. Therefore, leucyte immigrate and bring on blistering.

At the moment, the therapy options are limited. Often corticosteroids are used for reducing the symptoms, but this also conduct great side effects and recurrence. Iatrogenic immunosuppression is believed to be a main reason for the increase in mortality of EBA Patients. Because of that, there is a need to evolve a medical treatment, which is specific and save for these patients.

In my project, I do the in vivo validation of 10 different already in vitro successfully confirmed Inhibitors of the ROS-Production. I will test them at the local EBA mouse-model. Hopefully this leads to a new strategy in the treatment of EBA Patients.